Cardiol Therapeutics (CRDL) Cash from Operations: 2020-2024
Historic Cash from Operations for Cardiol Therapeutics (CRDL) over the last 5 years, with Dec 2024 value amounting to -$18.3 million.
- Cardiol Therapeutics' Cash from Operations rose 74.40% to -$1.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$14.7 million, marking a year-over-year change of. This contributed to the annual value of -$18.3 million for FY2024, which is 1.92% up from last year.
- Latest data reveals that Cardiol Therapeutics reported Cash from Operations of -$18.3 million as of FY2024, which was up 1.92% from -$18.7 million recorded in FY2023.
- Cardiol Therapeutics' 5-year Cash from Operations high stood at -$6.8 million for FY2020, and its period low was -$20.9 million during FY2022.
- In the last 3 years, Cardiol Therapeutics' Cash from Operations had a median value of -$18.7 million in 2023 and averaged -$19.3 million.
- Its Cash from Operations has fluctuated over the past 5 years, first crashed by 175.62% in 2021, then increased by 10.86% in 2023.
- Cardiol Therapeutics' Cash from Operations (Yearly) stood at -$6.8 million in 2020, then slumped by 175.62% to -$18.8 million in 2021, then dropped by 11.46% to -$20.9 million in 2022, then rose by 10.86% to -$18.7 million in 2023, then rose by 1.92% to -$18.3 million in 2024.